Top

High Blood Pressure & Cardiovascular Prevention

Published in:

01-03-2013 | Original Research Article

Antihypertensive Response to Combination of Olmesartan and Amlodipine Does Not Depend on Method and Time of Drug Administration

Authors: Francesco Rozza, Valentina Trimarco, Raffaele Izzo, Mario Santoro, Maria Virginia Manzi, Marina Marino, Gianfranco Di Renzo, Bruno Trimarco

Published in: High Blood Pressure & Cardiovascular Prevention | Issue 1/2013

Abstract

Fixed combinations of antihypertensive drugs have the potentiality to improve blood pressure (BP) control. However, when pharmacokinetic parameters of the two drugs are different, both method and time of administration of the two drugs may modify the antihypertensive response. In an open-label, single-blind, randomized study we compared antihypertensive effect of four administration schemes of a combination therapy of olmesartan and amlodipine in the same group of hypertensive patients, using ambulatory blood pressure monitoring (ABPM). The olmesartan + amlodipine combination has demonstrated to provide a good control of BP, with systolic and diastolic BP constantly below 130 and 85 mmHg over the 24 h. The simultaneous or separate administration of the 2 drugs fully overlapped, suggesting that the fixed combination and the separate administration induce a similar and sustained BP control.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMedCrossRef

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87.PubMedCrossRef

Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983–92.PubMedCrossRef

Tocci G, Rosei EA, Ambrosioni E, Borghi C, Ferri C, Ferrucci A, et al. Blood pressure control in Italy: analysis of clinical data from 2005–2011 surveys on hypertension. J Hypertens. 2012;30(6):1065–74.PubMedCrossRef

Cushman WC, Basile J. Achieving blood pressure goals: why aren’t we? J Clin Hypertens (Greenwich). 2006;8(12):865–72.

Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825–34.PubMedCrossRef

Spranger CB, Ries AJ, Berge CA, Radford NB, Victor RG. Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med. 2004;117(1):14–8.PubMedCrossRef

Neutel JM. Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Am J Hypertens. 1999;12(8 Pt 2):73S–9S.PubMedCrossRef

Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.PubMedCrossRef

10.

Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.

11.

Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.PubMedCrossRef

12.

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–31.PubMedCrossRef

13.

Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(2):90–8.

14.

Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–58.PubMedCrossRef

15.

Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.PubMedCrossRef

16.

Palatini P, Racioppa A, Raule G, Zaninotto M, Penzo M, Pessina AC. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther. 1992;52(4):378–83.PubMedCrossRef

17.

Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens Suppl. 2001;19(1):S3–14.PubMed

18.

Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995;285(2):181–8.PubMedCrossRef

19.

Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig. 2003;23(7):419–30.PubMedCrossRef

20.

Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs. 2007;67(9):1309–27.PubMedCrossRef

21.

De Luca N, Izzo R, Iaccarino G, Malini PL, Morisco C, Rozza F, et al. The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis. J Hypertens. 2005;23(7):1417–23.PubMedCrossRef

22.

de Simone G, Izzo R, Chinali M, De Marco M, Casalnuovo G, Rozza F, et al. Does information on systolic and diastolic function improve prediction of a cardiovascular event by left ventricular hypertrophy in arterial hypertension? Hypertension. 2010;56(1):99–104.

23.

Izzo R, de Simone G, Chinali M, Iaccarino G, Trimarco V, Rozza F, et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care. 2009;32(5):845–50.PubMedCrossRef

24.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.PubMed

25.

Owens P, Atkins N, O’Brien E. Diagnosis of white coat hypertension by ambulatory blood pressure monitoring. Hypertension. 1999;34(2):267–72.PubMedCrossRef

26.

Parati G, Omboni S, Palatini P, Rizzoni D, Bilo G, Valentini M, et al. Italian Society of Hypertension Guidelines for Conventional and Automated Blood Pressure Measurement in the Office, at Home and Over 24 Hours. High Blood Pressure Cardiovasc Prev. 2008;15(4):283–310. doi:10.2165/0151642-200815040-00008.CrossRef

27.

Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587–604.PubMedCrossRef

28.

Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol. 2009;54(5):427–36.PubMedCrossRef

29.

Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(1):11–25.PubMedCrossRef

30.

Barrios V, Brommer P, Haag U, Calderon A, Escobar C. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(7):427–39.PubMedCrossRef

31.

Kreutz R. Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc Health Risk Manag. 2011;7:183–92.PubMedCrossRef

32.

Stanton A, Cox J, Atkins N, O’Malley K, O’Brien E. Cumulative sums in quantifying circadian blood pressure patterns. Hypertension. 1992;19(1):93–101.PubMedCrossRef

33.

Mancia G, Gamba PL, Omboni S, Paleari F, Parati G, Sega R, et al. Ambulatory blood pressure monitoring. J Hypertens Suppl. 1996;14(2):S61–6 (discussion S6–8).

34.

Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension. 2000;36(5):901–6.PubMedCrossRef

35.

Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens. 1993;11(10):1133–7.PubMedCrossRef

36.

Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2001;19(11):1981–9.PubMedCrossRef

37.

Palatini P, Penzo M, Racioppa A, Zugno E, Guzzardi G, Anaclerio M, et al. Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med. 1992;152(9):1855–60.PubMedCrossRef

38.

Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens. 1987;5(1):93–8.PubMedCrossRef

39.

Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation. 2000;102(13):1536–41.PubMedCrossRef

40.

Bolbrinker J, Huber M, Scholze J, Kreutz R. Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. Fundam Clin Pharmacol. 2009;23(6):767–74.PubMedCrossRef

41.

Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598–605.PubMedCrossRef

42.

Dragomir A, Cote R, Roy L, Blais L, Lalonde L, Berard A, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418–25.PubMedCrossRef

43.

Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich). 2009;11(7):376–82.CrossRef

44.

Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens (Greenwich). 2010;12(1):40–6.CrossRef

Title: Antihypertensive Response to Combination of Olmesartan and Amlodipine Does Not Depend on Method and Time of Drug Administration
Authors: Francesco Rozza
Valentina Trimarco
Raffaele Izzo
Mario Santoro
Maria Virginia Manzi
Marina Marino
Gianfranco Di Renzo
Bruno Trimarco
Publication date: 01-03-2013
Publisher: Springer International Publishing AG
Published in: High Blood Pressure & Cardiovascular Prevention / Issue 1/2013
Print ISSN: 1120-9879
Electronic ISSN: 1179-1985
DOI: https://doi.org/10.1007/s40292-013-0013-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Antihypertensive Response to Combination of Olmesartan and Amlodipine Does Not Depend on Method and Time of Drug Administration

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Non-Alcoholic Fatty Liver Disease is Not Associated with Vitamin D Deficiency in Essential Hypertension

2012 Consensus Document of the Italian Society of Hypertension (SIIA): Strategies to Improve Blood Pressure Control in Italy

The Importance of 24-Hour Ambulatory Blood Pressure Monitoring in Patients at Risk of Cardiovascular Events

G-Protein-Coupled Receptor Kinase 2 and Hypertension

The Neglected Role of the Electrocardiogram in the Diagnostic Work-Up of Hypertensive Patients

The Relationship Between Cognitive Function, Depressive Behaviour and Sleep Quality with 24-h Urinary Sodium Excretion in Patients with Essential Hypertension